Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,029

Document Document Title
WO/2018/108089A1
Provided are a class of compounds, as represented by formula (I), having a bifunctional active quaternary ammonium salt structure of a β2 adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, ...  
WO/2018/087561A1
The present invention discloses processes comprising a) reacting ethyl isonipecotate with 1 -bromo-2- chloroethane in the presence of an organic base in a solvent to form ethyl 1 -(2-chloroethyl)piperidine- 4-carboxylate (II) or a salt t...  
WO/2018/011611A1
The object of the invention relates to the salts of encenicline formed with inorganic and organic acids of general formula (I), as well as to the use of these for the production of pharmaceutical preparations primarily suitable for the t...  
WO/2018/011227A1
The invention relates to a compound of Formula I : Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2...  
WO/2017/218920A1
This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.  
WO/2017/200184A1
The present invention relates to a novel chiral phase-transfer catalyst, and a method for preparing an α-amino acid by using the same. According to the present invention, an α-amino acid could be chirally synthesized in a high yield un...  
WO/2017/178897A3
Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)...  
WO/2017/176948A1
This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine- based chiral phase transfer catalysts. The invention also relates to novel quinine-based phase transf...  
WO/2017/148455A1
The invention relates to iodinated aromatic choline analogs of general formula wherein at least one R is iodine; the quaternary ammonium group comprises a hydroxyl substituent, and further substituent are as defined in the claims. The co...  
WO/2017/120532A1
Provided is a phosphate salt of quinuclidin-4-ylmethyl 4-methyl-1H-indole-3- carboxylate, in particular polymorphic Form A, a process for their preparation of said salt, in particular in polymorphic Form A, and a pharmaceutical compositi...  
WO/2017/083242A1
Compounds capable of inhibiting suppression of tumorgenicity 2 (ST2) are disclosed. The compounds are useful in the treatment of a variety of diseases and conditions, such as alleviation of graft-versus-host disease (GVHD), cardiovascula...  
WO/2017/075694A1
The present invention relates to compounds of formula (I) wherein G1 to G8 are as defined herein. The compounds are PK inhibitors and as such represent a new approach to treating pathogenic infections, including multidrug resistant patho...  
WO/2017/069226A1
A compound represented by general formula [I] (in the formula, X represents N or the like, Y represents CH or the like, RA represents an optionally substituted cycloalkyl group or the like, R1 represents an alkyl group or the like, R2 re...  
WO/2017/060287A1
The present invention relates to a process for the preparation of an amide from a carboxylic acid chloride and an organic molecule comprising both a primary amine group and a tertiary amine group, wherein the nitrogen atom of the tertiar...  
WO/2017/060290A1
The present invention relates to a crystalline forms of encenicline hydrochloride and a process for their preparation. The invention also concerns a pharmaceutical compositions comprising an effective amount of the crystalline form of en...  
WO/2017/051761A1
The prodrug or a salt thereof according to the present invention is represented by the formula: D-X-L. (In the formula, D represents a useful compound and becomes D-X-H. X represents NR1, O, S, or Se. R1 represents a hydrogen atom, a sub...  
WO/2017/023700A1
Disclosed herein are compositions which include nicotinic receptor agonists, specifically of the α4β2 or α7 nAChR subtypes, and methods for treating or suppressing cough.  
WO/2016/203112A1
The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2'- derivatives of formula (I) in which Cy R1, R2, R4, L and 'm' are have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The com...  
WO/2016/201096A1
The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of ot7-nAChR, and methods of preparing these compounds and compositions, ...  
WO/2016/193241A1
The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations w...  
WO/2016/193240A1
The invention relates to novel compounds which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.  
WO/2016/162878A1
The present invention discloses the process for preparation of 1- ¬Azoniabicyclo[2.2.2]octane,3-[(hydroxydi-2-thienylacety1)o xy]-1-(3¬iphenoxypropy1)-, bromide, (3R)- and its novel crystalline form-I  
WO/2016/156836A1
A process for preparing (3R)-3-[2-Hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)- 1- azoniabicyclo[2.2.2]octane bromide (aclidinium bromide) comprises reacting 2-hydroxy-2,2- dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R) yl meth...  
WO/2016/159268A1
Provided is a novel non-deliquescent acid addition salt of 3-aminoquinuclidine, which is a compound industrially useful as an intermediate for a medicine and the like. An acid addition salt of 3-aminoquinuclidine selected from the group ...  
WO/2016/140136A1
Provided is a new agent for treating chronic obstructive pulmonary disease. The present invention provides quinuclidine derivatives represented by general formula (1), and a pharmaceutical containing the same. (In the formula, R1 indicat...  
WO/2016/131789A1
The present invention relates to benzopyrrolidone derivatives and/or pharmaceutically acceptable salts thereof for the use in the treatment of infectious diseases or cancer, and pharmaceutical compositions containing at least one of said...  
WO/2016/128456A1
The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations w...  
WO/2016/124125A1
The present invention relates to a new crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxa mide hydrochloride and a preparation method for the new crystalline form. The crystalline form has advantageous prope...  
WO/2016/073294A1
Disclosed are nonlimiting embodiments comprising novel methods for treating underactive bladder in a subject, including administering an effective amount of a pharmaceutical composition comprising an Ml -selective muscarinic agonist to t...  
WO/2016/051187A1
There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: th...  
WO/2016/046390A1
The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respirato...  
WO/2016/039048A1
The present invention provides a compound which is represented by formula (I-1) (wherein R4 represents a hydrogen atom, a C1-6 alkyl group or the like; Ar1 represents a C6-10 aryl group, a 3-6 membered heterocyclyl group or the like; A r...  
WO/2016/031987A1
A compound represented by any of formulas (Ia)-(Ic) or formula (II), or a pharmaceutically acceptable salt thereof. (In the formulas, R1, R2, R3, R4a, R4c, R5, R15, ring A, X1, and X2 are as defined in the specification.)  
WO/2016/023787A1
The present invention relates to a process for the preparation of a compound of formula (I) wherein A1 and A2 are C-H, or one of A1 and A2 is C-H and the other is N; R1 is C1-C4alkyl, C1-C4haloalkyl or C3-C6cycloalkyl; each R2 is indepen...  
WO/2016/010538A1
Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the com...  
WO/2016/007630A1
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.  
WO/2015/185649A9
The invention relates to novel compounds which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. M...  
WO/2015/185649A1
The invention relates to novel compounds which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. M...  
WO/2015/185128A1
The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of prepar...  
WO/2015/185130A1
The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing ...  
WO/2015/185650A1
The invention relates to novel compounds which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. (...  
WO/2015/185780A1
The invention relates to symmetrical polar compounds of bispyridinium, bisquinuclidinium and bisquinolinium with a linker derived from 1,2-bis(p-tolyloxy)ethane, which are inhibitors of choline kinase. The invention also relates to the s...  
WO/2015/162452A1
The present invention relates to compounds of formula 1, or isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, S-oxides or N-oxides thereof, and processes for their preparation. T...  
WO/2015/163427A1
The present invention provides: a novel disubstituted 1, 2, 4-triazine compound that has an aldosterone synthase inhibitory activity and is useful in the prevention and/or treatment of various diseases or symptoms involving aldosterone, ...  
WO/2015/144101A1
New forms of aclidinium chloride of formula I. The process for preparing the crystalline aclidinium chloride consists in reaction of the quinuclidinyl ester of formula V with 3-phenoxypropyl chloride in acetonitrile.  
WO/2015/130110A1
Provided are: a solid dispersion composition containing solifenacin or a pharmaceutically acceptable salt thereof, wherein the active ingredient thereof comprises only an amorphous form of solifenacin or a pharmaceutically acceptable sal...  
WO/2015/129630A1
[Problem] To provide a novel method for producing (S)-2-(5-chloro-2-nitrophenyl)-4-cyclopropyl-1,1,1-trifluoro but-3-yne-2-ol. [Solution] An alkynyl ketone represented by belowmentioned formula (1) is reacted with (trifluoromethyl) trime...  
WO/2015/087291A1
A novel method for obtaining 3-carboxy-4-(R)-phenylpyrrolidine-2-one from 3-carboxy-4- (R,S)-phenylpyrrolidine-2-one in which the racemic mixture is separated using 3-(S)- benzoyloxyquinuclidine.  
WO/2015/071824A1
The present invention relates to process for the preparation of aclidiunium or intermediates thereof. More particularly, it relates to the preparation of aclidinium bromide.  
WO/2015/062560A1
An efficient and industrially applicable process for preparing aclidinium bromide of formula I, comprising the following steps a) preparation of the quinuclidinyl ester by transestenfication of methyl di(2-thienly)giycolate with R-(-)-3-...  

Matches 1 - 50 out of 3,029